Literature DB >> 28811355

Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.

Esi M Morgan1,2, Meredith P Riebschleger3,4, Jennifer Horonjeff3,4, Alessandro Consolaro3,4, Jane E Munro3,4, Susan Thornhill3,4, Timothy Beukelman3,4, Hermine I Brunner3,4, Emily L Creek3,4, Julia G Harris3,4, Daniel B Horton3,4, Daniel J Lovell3,4, Melissa L Mannion3,4, Judyann C Olson3,4, Homaira Rahimi3,4, Maria Chiara Gallo3,4, Serena Calandra3,4, Angelo Ravelli3,4, Sarah Ringold3,4, Susan Shenoi3,4, Jennifer Stinson3,4, Karine Toupin-April3,4, Vibeke Strand3,4, Clifton O Bingham3,4.   

Abstract

OBJECTIVE: The current Juvenile Idiopathic Arthritis (JIA) Core Set was developed in 1997 to identify the outcome measures to be used in JIA clinical trials using statistical and consensus-based techniques, but without patient involvement. The importance of patient/parent input into the research process has increasingly been recognized over the years. An Outcome Measures in Rheumatology (OMERACT) JIA Core Set Working Group was formed to determine whether the outcome domains of the current core set are relevant to those involved or whether the core set domains should be revised.
METHODS: Twenty-four people from the United States, Canada, Australia, and Europe, including patient partners, formed the working group. Guided by the OMERACT Filter 2.0 process, we performed (1) a systematic literature review of outcome domains, (2) a Web-based survey (142 patients, 343 parents), (3) an idea-generation study (120 parents), (4) 4 online discussion boards (24 patients, 20 parents), and (5) a Special Interest Group (SIG) activity at the OMERACT 13 (2016) meeting.
RESULTS: A MEDLINE search of outcome domains used in studies of JIA yielded 5956 citations, of which 729 citations underwent full-text review, and identified additional domains to those included in the current JIA Core Set. Qualitative studies on the effect of JIA identified multiple additional domains, including pain and participation. Twenty-one participants in the SIG achieved consensus on the need to revise the entire JIA Core Set.
CONCLUSION: The results of qualitative studies and literature review support the need to expand the JIA Core Set, considering, among other things, additional patient/parent-centered outcomes, clinical data, and imaging data.

Entities:  

Keywords:  JUVENILE IDIOPATHIC ARTHRITIS; OMERACT; OUTCOME MEASUREMENT

Mesh:

Substances:

Year:  2017        PMID: 28811355      PMCID: PMC5914507          DOI: 10.3899/jrheum.161389

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood.

Authors:  Arnd Heiligenhaus; Ivan Foeldvari; Clive Edelsten; Justine R Smith; Rotraud K Saurenmann; Bahram Bodaghi; Joke de Boer; Elizabeth Graham; Jordi Anton; Kaisu Kotaniemi; Friederike Mackensen; Kirsten Minden; Susan Nielsen; Egla C Rabinovich; Athimalaipet V Ramanan; Vibeke Strand
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

2.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

3.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

4.  Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.

Authors:  Maarten Boers; John R Kirwan; George Wells; Dorcas Beaton; Laure Gossec; Maria-Antonietta d'Agostino; Philip G Conaghan; Clifton O Bingham; Peter Brooks; Robert Landewé; Lyn March; Lee S Simon; Jasvinder A Singh; Vibeke Strand; Peter Tugwell
Journal:  J Clin Epidemiol       Date:  2014-02-28       Impact factor: 6.437

5.  Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

Authors:  Alessandro Consolaro; Nicolino Ruperto; Anna Bazso; Angela Pistorio; Silvia Magni-Manzoni; Giovanni Filocamo; Clara Malattia; Stefania Viola; Alberto Martini; Angelo Ravelli
Journal:  Arthritis Rheum       Date:  2009-05-15

6.  Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis.

Authors:  Carol A Wallace; Angelo Ravelli; Bin Huang; Edward H Giannini
Journal:  J Rheumatol       Date:  2006-02-15       Impact factor: 4.666

7.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

8.  Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Authors:  Nicolino Ruperto; Hermine I Brunner; Pierre Quartier; Tamás Constantin; Nico Wulffraat; Gerd Horneff; Riva Brik; Liza McCann; Ozgur Kasapcopur; Lidia Rutkowska-Sak; Rayfel Schneider; Yackov Berkun; Inmaculada Calvo; Muferet Erguven; Laurence Goffin; Michael Hofer; Tilmann Kallinich; Sheila K Oliveira; Yosef Uziel; Stefania Viola; Kiran Nistala; Carine Wouters; Rolando Cimaz; Manuel A Ferrandiz; Berit Flato; Maria Luz Gamir; Isabelle Kone-Paut; Alexei Grom; Bo Magnusson; Seza Ozen; Flavio Sztajnbok; Karine Lheritier; Ken Abrams; Dennis Kim; Alberto Martini; Daniel J Lovell
Journal:  N Engl J Med       Date:  2012-12-20       Impact factor: 91.245

9.  Online focus groups as a tool to collect data in hard-to-include populations: examples from paediatric oncology.

Authors:  Kiek Tates; Marieke Zwaanswijk; Roel Otten; Sandra van Dulmen; Peter M Hoogerbrugge; Willem A Kamps; Jozien M Bensing
Journal:  BMC Med Res Methodol       Date:  2009-03-03       Impact factor: 4.615

10.  Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.

Authors:  Hermine I Brunner; Nicolino Ruperto; Zbigniew Zuber; Caroline Keane; Olivier Harari; Andrew Kenwright; Peng Lu; Ruben Cuttica; Vladimir Keltsev; Ricardo M Xavier; Inmaculada Calvo; Irina Nikishina; Nadina Rubio-Pérez; Ekaterina Alexeeva; Vyacheslav Chasnyk; Gerd Horneff; Violetta Opoka-Winiarska; Pierre Quartier; Clovis A Silva; Earl Silverman; Alberto Spindler; Eileen Baildam; M Luz Gámir; Alan Martin; Christoph Rietschel; Daniel Siri; Elzbieta Smolewska; Daniel Lovell; Alberto Martini; Fabrizio De Benedetti
Journal:  Ann Rheum Dis       Date:  2014-05-16       Impact factor: 19.103

View more
  3 in total

Review 1.  Assessing Patient-Reported Outcomes in Pediatric Rheumatic Diseases: Considerations and Future Directions.

Authors:  Christina K Zigler; Rachel L Randell; Bryce B Reeve
Journal:  Rheum Dis Clin North Am       Date:  2022-02       Impact factor: 2.032

2.  Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study.

Authors:  Ashley P Jones; Dannii Clayton; Gloria Nkhoma; Frances C Sherratt; Matthew Peak; Simon R Stones; Louise Roper; Bridget Young; Flora McErlane; Tracy Moitt; Athimalaipet V Ramanan; Helen E Foster; Paula R Williamson; Samundeeswari Deepak; Michael W Beresford; Eileen M Baildam
Journal:  Health Technol Assess       Date:  2020-07       Impact factor: 4.014

3.  Outcome measures for assessing change over time in studies of symptomatic children with hypermobility: a systematic review.

Authors:  Muhammad Maarj; Andrea Coda; Louise Tofts; Cylie Williams; Derek Santos; Verity Pacey
Journal:  BMC Pediatr       Date:  2021-11-29       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.